Nurexone Biologic Inc - NRXBF STOCK NEWS

NurExone Biologic announced a non-brokered private placement of up to $2M, with a first tranche closing for $1.61M. The offering includes 3,636,363 units at $0.55 per unit, each comprising one common share and one purchase warrant. Warrants allow the purchase of one common share at $0.70 for 36 months, subject to acceleration if the average share price exceeds $1.05 for 10 consecutive trading days. Proceeds will be used for working capital. The offering may be a related party transaction but is expected to be exempt from certain formal requirements. All securities issued are subject to a statutory hold period of four months and one day.

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) is set to participate in several prestigious conferences in October 2024, showcasing its advancements in exosome-based therapies for regenerative medicine. The company will sponsor and present at the World Orphan Drug Congress in Barcelona, highlighting its work on neuron regeneration for acute spinal cord injuries. Dr. Noa Avni will present at the Precision EV Forum 2024 in Cambridge, addressing translational challenges for therapeutic EVs. NurExone will also chair a session on GMP-compliant EV production.

Additionally, the company will present at the Israeli Society of Gene and Cell Therapy's meeting and the Bioprocess International Conference in Boston, where CEO Dr. Lior Shaltiel will discuss their ExoPTEN nanodrug for acute spinal cord injuries and other CNS conditions. These engagements aim to advance therapeutic exosomes and explore potential collaborations in the field.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced promising results from a preclinical study of ExoPTEN for spinal cord injuries. The study demonstrated that ExoPTEN can effectively target and accumulate at injury sites up to one week after the injury occurred, potentially broadening the range of treatable patients and extending the window for effective treatment.

Key findings include:

• ExoPTEN showed strong homing capacity to injury sites even 7 days post-injury
• Later administration times resulted in higher levels of accumulation
• The highest accumulation was observed in subjects treated 7 days post-injury
• Results suggest a broad therapeutic window for intervention

These findings could significantly impact clinical trial design and patient care, offering hope for more flexible treatment regimens in spinal cord injury cases.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has been invited to present at two prestigious conferences in September, showcasing its prominence in regenerative medicine and exosome technology. CEO Dr. Lior Shaltiel will speak at the Bioprocess International Conference in Boston from September 23-26, focusing on the company's ExoPTEN nanodrug for acute spinal cord injuries and other central nervous system indications.

Dr. Shaltiel will also participate as a panelist at the Pioneering Israel Medicine Conference in New York on September 22, sharing insights into NurExone's groundbreaking work in exosomes for regenerative medicine. These invitations highlight NurExone's growing influence in the field and provide opportunities to engage with industry leaders, researchers, and potential collaboration partners.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced significant advancements in their exosome manufacturing process, important for their ExoPTEN product development. The company demonstrated consistent exosome production from multiple biological sources, comparing exosomes from bone marrow-derived mesenchymal stem cells (MSCs) of different donors. Despite natural variability in starting materials, the exosomes showed consistent yields and similar size distribution.

NurExone also tested the effectiveness of exosomes in an animal model of spinal cord injury, demonstrating excellent and comparable homing abilities to the injured area. The company compared exosomes produced using 2D and 3D culture methods, finding similar homing and targeting capabilities. This advancement supports NurExone's ability to scale up production for potential commercial applications in regenerative medicine treatments.

NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) has announced new data for its ExoPTEN nanodrug, demonstrating significant progress towards commercial-grade manufacturing. The study focused on ExoPTEN's ability to target inflammation and injury sites when loaded with small interfering RNA (siRNA) produced by a new GMP-compliant manufacturer.

Key findings include:

• ExoPTEN showed exceptional homing capacity to injured spinal cord tissue in rats
• High concentration of the drug was observed in damaged tissue
• Results validate the quality of siRNA from the new GMP Partner
• Confirms NurExone's exosomes as an effective drug delivery system

This advancement marks a important step towards meeting quality and regulatory standards for commercial manufacturing, as the company progresses towards clinical trials.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced a significant milestone in its regenerative medicine efforts. The company has successfully transferred the manufacturing of the siRNA sequence for its ExoPTEN nanodrug to a German GMP-capable producer. This move is important for producing drugs for clinical trials and commercial sale.

The siRNA from the new vendor achieved an approximately 80% reduction in PTEN expression, demonstrating comparable potency to the previous research-grade producer. This transfer establishes the foundation for future GMP manufacture of NurExone's patented product, which uses PTEN inhibition to facilitate nerve growth and regeneration after injury or damage.

Dr. Lior Shaltiel, CEO of NurExone, emphasized the importance of this achievement in meeting the strict quality and regulatory standards necessary for clinical trials, marking a critical step in the development of the ExoPTEN nanodrug.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced the expansion of its ExoPTEN patent coverage. The Israel Patent Office issued a Notice of Allowance for a patent titled 'Vesicles Comprising a PTEN Inhibitor and Uses of Same', which covers innovative Extracellular Vesicles (EVs) with a PTEN inhibitor. This patent is important for NurExone's ExoPTEN drug, aimed at promoting nerve growth and regeneration after acute spinal cord injury.

The company also revealed its engagement with Allele Capital Partners, for investor relation services, including capital markets consultation and corporate video dissemination on social media. The initial agreement is for one month at $11,000 per month, with potential for extension and a fee increase to $14,500 upon uplisting to NYSE or NASDAQ.

NurExone Biologic Inc. (TSXV: NRX, OTCQB: NRXBF) has announced promising preliminary results from a small-scale study exploring the use of its nanodrug, ExoPTEN, for optic nerve recovery in a rat model at Sheba Medical Center. The study, using an Optic Nerve Crush (ONC) model to simulate glaucoma conditions, showed that ExoPTEN treatment resulted in functional restoration of damaged eyes to healthy levels.

Key findings include:

• ExoPTEN-treated eyes exhibited retinal response similar to healthy eyes
• Results were observed just 18 days after ONC damage
• Treatment was administered minimally-invasively using suprachoroidal injection

These preliminary results suggest potential for ExoPTEN in the $3.4 billion glaucoma market, with further studies planned to validate findings and explore human applications.